Ono Pharmaceutical Co (Ono Pharmaceutical Co) Total Stockholders Equity : $5,450 Mil (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Ono Pharmaceutical Co Total Stockholders Equity?

Ono Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $5,450 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Ono Pharmaceutical Co's Book Value per Share for the quarter that ended in Dec. 2023 was $3.83. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Ono Pharmaceutical Co's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.01.

Ono Pharmaceutical Co Total Stockholders Equity Historical Data

The historical data trend for Ono Pharmaceutical Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ono Pharmaceutical Co Total Stockholders Equity Chart

Ono Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Stockholders Equity

Get a 7-Day Free Trial

5,014.65

5,224.28

5,833.84

5,531.46

5,550.24

Ono Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															5,346.97	5,550.24	5,394.01	5,257.47	5,449.71

Ono Pharmaceutical Co (OTCPK:OPHLY) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Ono Pharmaceutical Co's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(5449.707	-	0)	/	1424.6
	=	3.83

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Ono Pharmaceutical Co's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(15.738	+	43.895)	/	5449.707
	=	0.01

Ono Pharmaceutical Co Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Ono Pharmaceutical Co's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

OPHLF:USA 4528:Japan ON4:Germany

Address

8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564

Website

http://www.ono.co.jp

Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a global business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Headlines

From GuruFocus

Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million

By PRNewswire • 12-01-2023

Ono Pharmaceutical Co Stock Appears To Be Modestly Undervalued

By GF Value • 07-05-2021

T. Rowe Price Japan Fund Purchases 5 Stocks in 3rd Quarter

By Holly LaFon Holly LaFon • 10-18-2017

Samuel Isaly's Eaton Vance Worldwide Health Sciences Fund Q1 Investment Report

By Holly LaFon Holly LaFon • 05-13-2016